How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,785 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Papular Mycosis Fungoides is a Distinctive Variant of Early-stage Mycosis Fungoides: Extended Retrospective Study With Long-term Follow-up. (Abstract)

Papular Mycosis Fungoides is a Distinctive Variant of Early-stage Mycosis Fungoides: Extended Retrospective Study With Long-term Follow-up. Papular mycosis fungoides (PMF) is a rare variant of mycosis fungoides (MF). The exact nosology and prognosis of PMF are still unclear. We retrospectively identified cases of PMF from the files of the Department of Dermatology of the Medical University of Graz, Austria, and checked the follow-up data. The patients comprised 13 men and 5 women (median age

2019 American Journal of Surgical Pathology

3. Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma

Chlormethine (Ledaga) - mycosis fungoides-type cutaneous T-cell lymphoma 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 15 December 2016 EMA/CHMP/13156/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) purified HPRT hypoxanthine-guanine phosphoribosyltransferase IARC International Agency for Research on Cancer IC50 half-maximal inhibitory concentration ICH International Conference on Harmonisation IID Inactive Ingredient Database i.p. intraperitoneal i.v. intravenous IR InfraredKF Karl Fischer titration LD50 median lethal dose MDA malondialdehyde MDEA N-methyldiethanolamine MF mycosis fungoides MF-type CTC mycosis fungoides-type cutaneous T-cell lymphoma MNNG N-methyl-N´-nitro-N-nitrosoguanidine MTD

2017 European Medicines Agency - EPARs

4. Corneal infiltration and xanthoma formation in mycosis fungoides Full Text available with Trip Pro

Corneal infiltration and xanthoma formation in mycosis fungoides To report a case of corneal infiltration and xanthoma formation in mycosis fungoides (cutaneous T-cell lymphoma).A middle aged Japanese man with mycosis fungoides (MF) involving the face was referred to Ophthalmology for evaluation of unilateral, painless conjunctival injection. Biopsy of the conjunctiva revealed a malignant T cell population consistent with MF tumor invasion. Years later, he returned following several episodes

2018 American journal of ophthalmology case reports

5. Large-Cell Transformed Mycosis Fungoides Coexisting with Mycosis Fungoides Bullosa: A Case Report and Review of the Literature Full Text available with Trip Pro

Large-Cell Transformed Mycosis Fungoides Coexisting with Mycosis Fungoides Bullosa: A Case Report and Review of the Literature Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. Both large-cell transformed mycosis fungoides and mycosis fungoides bullosa are rare presentations and predict unfavorable prognosis. We report the case of a 61-year-old woman who presented with generalized erythematous scaly annular plaques, and histopathology confirmed the diagnosis of mycosis (...) ). One day after receiving chemotherapy, multiple tense bullae on normal-appearing skin and mycosis fungoid plaques erupted. A histological study demonstrated subepidermal blistering with epidermotropism of atypical lymphocytes. Direct immunofluorescence study was negative. The results confirmed the diagnosis of mycosis fungoides bullosa. We present the first reported case of large-cell transformed mycosis fungoides coexisting with mycosis fungoides bullosa.

2017 Case reports in dermatology

6. Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness

Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Extracorporeal Photopheresis for Sezary Syndrome or Mycosis Fungoides: Clinical and Cost-Effectiveness Published on: September 30, 2015 Project (...) Number: RB0915-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of extracorporeal photopheresis (ECP) for the management of Sezary Syndrome or Mycosis fungoides? What is the cost-effectiveness of ECP for the management of Sezary Syndrome or Mycosis fungoides? Key Message One systematic review, four non-randomized studies, and one economic evaluation were identified regarding extracorporeal

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. The different faces of mycosis fungoides: results of a single-center study. (Abstract)

The different faces of mycosis fungoides: results of a single-center study. Mycosis fungoides (MF) accounts for the majority of cutaneous lymphomas. Apart from the predominant Alibert-Bazin type, several clinicopathological variants of diverse prevalence and biological behavior have been described. Data on clinical and epidemiological aspects of MF clinical subtypes are still weak.To outline the clinical and epidemiological profile of the different MF types in a large volume of Greek (...) (4.7%) MF. Atypical MF lesions as the sole manifestation of folliculotropic mycosis fungoides (FMF) - alopecia areata-like lesions (n = 10), keratosis pilaris-like lesions (n = 9) or acneiform rash (n = 4) - were also observed. Both poikilodermic and folliculotropic subtypes mainly involved younger patients. A significant diagnostic latency concerning poikilodermic and psoriasiform MF cases was recorded. Only 23 (3.3%) cases were of juvenile onset, with classical and poikilodermic MF equally

2020 International Journal of Dermatology

8. Dermoscopy in differential diagnosis of inflammatory dermatoses and mycosis fungoides. (Abstract)

Dermoscopy in differential diagnosis of inflammatory dermatoses and mycosis fungoides. The use of dermoscopy for the evaluation of various inflammatory dermatoses has witnessed a gradual increase in recent years. The present study describes and highlights the importance of dermoscopic findings in the differential diagnosis of plaque psoriasis (PP), lichen planus (LP), mycosis fungoides (MF), pityriasis rosea (PR), and nummular dermatitis (ND) that mostly involve the trunk.The study included 150

2020 International Journal of Dermatology

9. A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: Reduction of disease burden and improvement in quality of life. (Abstract)

A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: Reduction of disease burden and improvement in quality of life. Low-dose total skin electron beam therapy (TSEBT) for mycosis fungoides is popular because of reduced toxicity with effective palliation. We condensed TSEBT, reducing visits by half and overall treatment length by one third.To determine the efficacy and safety of a novel condensed low-dose TSEBT for mycosis fungoides.We

2020 Journal of American Academy of Dermatology

10. Suppressed microRNA-195-5p expression in mycosis fungoides promotes tumor cell proliferation. (Abstract)

Suppressed microRNA-195-5p expression in mycosis fungoides promotes tumor cell proliferation. Several cancers, including mycosis fungoides (MF), have reported dysregulation of miR-195-5p. miR-195-5p plays a role in cell cycle regulation in several malignant diseases.This study aimed to investigate: i) the expression level of miR-195-5p in lesional MF skin biopsies and II) the potential regulatory roles of miR-195-5p in MF.Quantitative real-time polymerase chain reaction (RT-qPCR) was used

2020 Experimental Dermatology

11. Mycosis Fungoides of the True Vocal Folds: A Case Report. (Abstract)

Mycosis Fungoides of the True Vocal Folds: A Case Report. To report a case of laryngeal involvement of mycosis fungoides and its symptomatic treatment with laser-assisted surgical ablation.Case report and literature review.A 76-year-old woman with longstanding MF previously treated with Brentuximab Vedotin who developed persistent cough and dysphonia. The patient's laryngeal disease burden was treated with KTP-laser ablation and further reduced with doxorubicin and radiotherapy.Although (...) laryngeal, and especially glottic, involvement is a rare finding, suspicion should be maintained in symptomatic patients with cutaneous mycosis fungoides. This the first reported surgical laser treatment of laryngeal symptoms in this context, which can greatly improve a patient's quality of life.

2020 Rhinology and Laryngology

12. Evaluation of the PCR-based T Cell Receptor-β clonality test in the diagnosis of early Mycosis Fungoides. (Abstract)

Evaluation of the PCR-based T Cell Receptor-β clonality test in the diagnosis of early Mycosis Fungoides. -T-cell receptor (TCR) clonality is important for the diagnosis of mycosis fungoides (MF). Routine clonality analysis is performed using a polymerase chain reaction (PCR) TCR-γ assay; yet with this method 10%-50% of T-cell lymphomas escape detection. TCR-β gene rearrangement is an additional assay. Data about its efficacy is controversial.- To evaluate the role of TCR-β assay

2020 Journal of American Academy of Dermatology

13. Interleukin-33 polymorphisms and serum concentrations in mycosis fungoides. (Abstract)

Interleukin-33 polymorphisms and serum concentrations in mycosis fungoides. Mycosis fungoides (MF) skin lesions are characterized by low-grade inflammation, which may be sustained by proinflammatory cytokines as probably interleukin-33 (IL-33). We compared serum concentrations of IL-33 and its receptor ST2 and the frequency of selected IL-33 single nucleotide polymorphisms (SNPs) between patients with MF and healthy controls.In 88 patients with MF and 66 healthy controls, we analyzed SNPs

2020 International Journal of Dermatology

14. CD8<sup>+</sup> cytotoxic mycosis fungoides: a retrospective analysis of clinical features and follow-up results of 29 patients. Full Text available with Trip Pro

CD8+ cytotoxic mycosis fungoides: a retrospective analysis of clinical features and follow-up results of 29 patients. Less than 5% of cases of mycosis fungoides (MF) present with a cytotoxic/suppressor CD8+ phenotype. This study aimed to evaluate the clinical characteristics, treatment modalities, and clinical course in CD8+ MF patients.In a retrospective analysis of 353 MF patients in a referral center at Ankara University, Turkey, 29 patients that were diagnosed with CD8+ MF were

2020 International Journal of Dermatology

15. Response to Topical Corticosteroid Monotherapy in Mycosis Fungoides. (Abstract)

Response to Topical Corticosteroid Monotherapy in Mycosis Fungoides. Topical corticosteroids alone or in combination with other therapies are widely used to treat Mycosis Fungoides (MF), but data on response rates to their use as monotherapy in MF are limited.Evaluate the efficacy of topical corticosteroid monotherapy in MF; compare gender, age, stage distributions, and histopathological features between responders and non-responders.A retrospective cross-sectional review of MF patients from

2020 Journal of American Academy of Dermatology

16. Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. (Abstract)

Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides. Mycosis fungoides is the most common subtype of cutaneous T-cell lymphoma. Skin-directed treatments often improve but do not cure mycosis fungoides skin lesions. The purpose of this study was to (i) assess whether remission was associated with malignant T-cell clone depletion at treated sites using either low-dose radiotherapy (LDRT, 8 Gy) or topical steroids and (ii) assess (...) whether a clone-ablative therapy, like LDRT, is associated with overall survival in patients with high-risk early-stage CTCL.Pre- and posttreatment biopsies from 20 lesional skin samples of 18 patients with mycosis fungoides who received either 8 Gy LDRT (n = 16) or topical steroids (n = 4) underwent high-throughput T-cell receptor sequencing of the TCRB gene to quantify the malignant T-cell clone. For the retrospective chart review, overall survival of 47 high-risk early-stage patients was compared

2020 Clinical Cancer Research

17. Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®): Health Professional Version

Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®): Health Professional Version Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ (...) Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®) Health Professional Version PDQ Adult Treatment Editorial Board . Published online: September 20, 2019. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of mycosis fungoides (including Sézary Syndrome). It is intended as a resource to inform and assist clinicians who

2018 PDQ - NCI's Comprehensive Cancer Database

18. Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis Full Text available with Trip Pro

Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis Mycosis fungoides (MF) is a significant diagnostic challenge; it has various differential diagnosis especially at an early stage. Our aim was to describe mimics of MF clinically and histologically, and to define significant diagnostic criteria of the disease.This was a retro-prospective cohort of 370 patients in whom the diagnosis of MF was suspected clinically.MF was histologically

2017 International journal of women's dermatology

19. Mycosis fungoides progression could be regulated by microRNAs. Full Text available with Trip Pro

Mycosis fungoides progression could be regulated by microRNAs. Differentiating early mycosis fungoides (MF) from inflammatory dermatitis is a challenge. We compare the differential expression profile of early-stage MF samples and benign inflammatory dermatoses using microRNA (miRNA) arrays. 114 miRNAs were found to be dysregulated between these entities. The seven most differentially expressed miRNAs between these two conditions were further analyzed using RT-PCR in two series comprising 38

2018 PLoS ONE

20. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. (Abstract)

Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).CITN-10 is a single-arm, multicenter phase II trial of 24 patients with advanced MF or SS. Patients were treated with pembrolizumab 2 mg/kg every 3 weeks for up to 24 months. The primary end point was overall response rate by consensus global response

2019 Journal of Clinical Oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>